CN115449496A - Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof - Google Patents
Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof Download PDFInfo
- Publication number
- CN115449496A CN115449496A CN202211310424.9A CN202211310424A CN115449496A CN 115449496 A CN115449496 A CN 115449496A CN 202211310424 A CN202211310424 A CN 202211310424A CN 115449496 A CN115449496 A CN 115449496A
- Authority
- CN
- China
- Prior art keywords
- ccfm1273
- lactobacillus
- product
- fatty liver
- alcoholic fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 54
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 54
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 42
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 20
- 102000016267 Leptin Human genes 0.000 title abstract description 31
- 108010092277 Leptin Proteins 0.000 title abstract description 31
- 229940039781 leptin Drugs 0.000 title abstract description 31
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract description 31
- 241000394636 Lactobacillus mucosae Species 0.000 claims description 23
- 210000000577 adipose tissue Anatomy 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 235000013622 meat product Nutrition 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 15
- 210000001789 adipocyte Anatomy 0.000 abstract description 14
- 210000000028 corpus adiposum pararenale Anatomy 0.000 abstract description 10
- 201000010063 epididymitis Diseases 0.000 abstract description 10
- 238000009825 accumulation Methods 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 5
- 210000003097 mucus Anatomy 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 10
- 238000000465 moulding Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000005861 leptin receptors Human genes 0.000 description 6
- 108010019813 leptin receptors Proteins 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002068 microbial inoculum Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000015700 Artemisia abrotanum Nutrition 0.000 description 1
- 244000249062 Artemisia abrotanum Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 238000013232 NAFLD rodent model Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof, and belongs to the technical field of microorganisms. The invention screens out a mucous membrane mucus lactobacillus CCFM1273 with the preservation number of GDMCC No:62775. the mucous membrane lactobacillus strain CCFM1273 provided by the invention has the effect of relieving non-alcoholic fatty liver, and is specifically embodied in that: relieving the weight increase of non-alcoholic fatty liver caused by high fat diet, liver weight, epididymal fat and perirenal fat; the fat accumulation of the liver caused by the non-alcoholic fatty liver is obviously improved, and the size of fat cells is reduced; significantly reducing the leptin level of the non-alcoholic fatty liver individual; relieving leptin resistance.
Description
Technical Field
The invention relates to a mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof, belonging to the technical field of microorganisms.
Background
As dietary structure shifts to high fat and high protein, the incidence of Non-alcoholic Fatty Liver Disease (NAFLD) induced thereby increases year by year and progresses in a low age state, and NAFLD has become one of the most common chronic Liver diseases worldwide. For example, the prevalence of NAFLD in the united states has increased significantly in recent years and now accounts for one fourth of the total population. NAFLD prevalence is higher in obese people. Research shows that the death rate of the patient population suffering from NAFLD is obviously higher than that of the normal population. NAFLD is a major causative factor of various chronic liver diseases such as cirrhosis and liver cancer. Because the pathogenesis of NAFLD is complex, no ideal therapeutic medicine and scheme exist at present.
Adipose tissue has been considered in the past as an organ that passively stores energy, and recent studies have shown that adipose tissue is a dynamic organ that can participate in lipid metabolism and regulate the energy balance throughout the body. The fat cell factors leptin produced by fat tissue can regulate glycolipid balance and energy metabolism, control appetite and thus achieve the effect of losing weight. Patients suffering from metabolic disorders such as obesity, metabolic syndrome and NAFLD, etc. develop leptin resistance leading to elevated leptin levels in the blood circulation.
Gut microbial dysbiosis refers to the destruction of the normal gut flora, which may be caused by a range of environmental, immunological or host factors as well as bile flow, altered gastric pH or intestinal motility disorders. There is a large body of evidence that gut microbial dysregulation, linked to the pathogenesis of human liver disease, plays an important role in NAFLD and its associated metabolic disorders. Therefore, probiotics are used for intervening non-alcoholic fatty liver, so as to regulate leptin resistance and further relieve NAFLD.
Chinese patent application CN 113265361A discloses a composite probiotic preparation for relieving non-alcoholic fatty liver, a preparation method and application thereof, but the relieving effect of single bacteria on non-alcoholic fatty liver is not researched. The research focuses on the relieving effect of single probiotics on NAFLD, and a mucous membrane lactobacillus strain with good relieving effect is obtained.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and obtains a mucous membrane lactobacillus strain CCFM1273 capable of preventing non-alcoholic fatty liver through animal experiment in vivo research, which has the effects of reducing weight, liver weight, epididymis and perirenal fat, reducing lipid deposition in the liver, reducing size of fat cells, relieving leptin resistance and the like.
In order to achieve the above purpose, the invention provides a strain of lactobacillus mucosus (limolactibacillus mucosae) CCFM1273 which has been deposited in the Guangdong province collection of microorganisms in 9 and 8 days 2022 with the deposit number being GDMCCNo:62775 the storage address is building No. 59, building No. 5 of the Jieli Zhonglu 100, guangzhou city.
In one embodiment, the lactobacillus mucosae CCFM1273 has the following biological properties:
the characteristics of the thallus are as follows: is creamy yellow;
colony characteristics: bacterial colony on MRS solid plate is creamy yellow and convex, and has regular edge and gram positive bacteria;
growth characteristics: the culture was carried out in MRS medium for about 16h to the end of log under aerobic conditions at a constant temperature of 37 ℃.
The invention also provides a microbial preparation containing the lactobacillus mucosae CCFM1273.
In one embodiment, the mucoadhesiveThe viable count of Lactobacillus plantarum CCFM1273 is not less than 1 × 10 10 CFU/g or 1X 10 10 CFU/mL。
The invention also provides application of the lactobacillus mucosus CCFM1273 in preparing a medicament for preventing and/or treating non-alcoholic fatty liver disease.
In one embodiment, the number of viable bacteria of lactobacillus mucosus CCFM1273 in the medicament is not less than 1 × 10 10 CFU/g。
In one embodiment, the medicament contains the lactobacillus mucosae CCFM1273, a pharmaceutical carrier and/or a pharmaceutical adjuvant.
The invention also provides application of the lactobacillus mucosae CCFM1273 in preparing health-care products which are helpful for controlling fat in vivo and/or maintaining the healthy level of blood fat.
The invention also provides a product containing the lactobacillus mucosae CCFM1273.
In one embodiment, the viable count of the lactobacillus mucosae CCFM1273 in the product is not less than 10 10 CFU/g。
In one embodiment, the product is a food, nutraceutical, or pharmaceutical product.
In one embodiment, the medicine contains the lactobacillus mucosus CCFM1273, a medicine carrier and/or a pharmaceutical adjuvant.
In one embodiment, the food product comprises a health food product comprising lactobacillus mucosus CCFM1273 described above.
In one embodiment, the food product comprises a dairy product, a bean product, a meat product or a fruit and vegetable product produced by using the fermentation agent of the lactobacillus mucosus CCFM1273.
In one embodiment, the preparation method of the fermentation agent comprises the steps of inoculating the lactobacillus mucosae CCFM1273 into a culture medium according to an inoculation amount accounting for 1-5% of the total mass of the culture medium, and culturing at 37 ℃ for 18 hours to obtain a culture solution; centrifuging the culture solution to obtain thalli; the cells were resuspended in physiological saline to obtain a starter.
In one embodiment, the medium is MRS medium.
In addition, the invention also provides application of the lactobacillus mucosus CCFM1273 in food additives, wherein the application comprises but is not limited to application as a food leavening agent.
Has the advantages that: the mucous membrane lactobacillus strain CCFM1273 can effectively reduce the weight, the weight of the liver, the weight of epididymis and perirenal fat, reduce lipid deposition in the liver, reduce the size of fat cells, relieve leptin resistance and show better treatment or prevention effect on non-alcoholic fatty liver, so that the mucous membrane lactobacillus strain can be used for preparing probiotic food, health care products and medicines for preventing and treating the non-alcoholic fatty liver, and has very wide application prospect.
Biological material preservation
Lactobacillus mucosus CCFM1273, classified and named as Limosilactibacillus mucosae, has been deposited in Guangdong province collection of microorganisms at 9/8 of 2022 with the deposit number GDMCC No:62775 the storage address is building No. 59, building No. 5 of the Jieli Zhonglu 100, guangzhou city.
Drawings
FIG. 1 shows the change in body weight during modeling of each group, indicating that Lactobacillus mucosae CCFM1273 decreases mouse body weight, liver weight, epididymal fat and perirenal fat weight; in the figure: the letters above the histogram are not the same indicating a significant difference (P < 0.05).
FIG. 2 shows oil red staining of liver tissue from each group, indicating that Lactobacillus mucosae CCFM1273 reduces fat deposition in the liver; in the figure: the letters above the histogram are not the same indicating a significant difference (P < 0.05).
FIG. 3 shows HE staining of perirenal adipose tissue in each group, indicating that Lactobacillus mucosae CCFM1273 reduces adipocyte size; in the figure: the upper letters of the histogram being different represent significant differences (P < 0.05).
FIG. 4 shows the change of leptin content in serum of each group, which indicates that Lactobacillus mucosae CCFM1273 significantly reduces the leptin content in mouse serum; in the figure: the letters above the histogram are not the same indicating a significant difference (P < 0.05).
FIG. 5 shows the change of the relative expression amount of mRNA of adipose tissue leptin in each group, which indicates that Lactobacillus mucosae CCFM1273 can reduce the expression amount of adipose tissue leptin in mice; in the figure: the upper letters of the histogram being different represent significant differences (P < 0.05).
FIG. 6 shows the effect of Lactobacillus mucosae CCFM1273 on the relative expression of mouse liver leptin receptor mRNA, which indicates that Lactobacillus mucosae CCFM1273 can significantly increase the expression of mouse adipose tissue leptin receptor; in the figure: the upper letters of the histogram being different represent significant differences (P < 0.05).
Detailed Description
The invention will be better understood from the following examples.
In the present invention, "%" or percentages used to indicate concentrations or ratios are weight percentages unless otherwise specified.
The present invention relates to the following media:
MRS liquid medium: 10g of tryptone, 10g of beef extract, 5g of yeast powder, 20g of glucose, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 2g of dipotassium hydrogen phosphate, 0.5g of magnesium sulfate heptahydrate, 0.25g of manganese sulfate monohydrate, 80 mL of Tween, and water till 1000mL.
MRS solid medium was obtained by adding 1.5% agar based on the total weight of liquid medium on the above basis.
Example 1: collection, separation and identification of lactobacillus mucosus CCFM1273
Taking 1g of cow dung sample collected from the university of Yunnan, coating the sample on an MRS solid culture medium after gradient dilution, placing the sample in an aerobic environment to culture for 72 hours at 37 ℃, observing and recording the colony morphology, selecting and marking off the colony for purification, then culturing the sample for 48 hours at 37 ℃ in an MRS liquid culture medium, performing gram staining on the obtained colony and recording the strain morphology, discarding gram negative strains and gram positive cocci in the colony, selecting and obtaining gram positive bacilli, discarding catalase positive strains after catalase analysis, reserving catalase negative strains, discarding the negative strains by fructose-6-phosphokinase detection, and identifying the obtained bacteria as mucous membrane lactobacillus by 16SrDNA sequencing, namely CCFM1273. Subculturing the obtained mucous membrane mucus lactobacillus, collecting thallus, centrifuging at 3000rpm in a centrifuge tube for 10min, washing, repeating for 3 times, adding the thallus into matrix protectant, freezing for preservation, and storing in Guangdong province microorganism strain preservation center. Another strain of the lactobacillus mucosus screened in the same batch is named as FGSYC17L3.
16S rDNA amplification conditions: 5min at 95 ℃;35 cycles (95 ℃ 30s,55 ℃ 30s,72 ℃ 2 min); 72 ℃ for 10min
An amplification primer: 27F: (5): (5 'TACGGCTACCTTGTTACGACT T-3') purification and sequence alignment of the amplification products was carried out according to the method described in the literature (Turroni F et al. Amplification of the conversion of the Bipolar amplification in the Human endogenous polypeptide Microb.2009;75 (6): 1534-45).
Example 2: preparation of mucous membrane lactobacillus strain CCFM1273 bacterial suspension
(1) Activation culture:
adopting MRS liquid culture medium, and static culturing in a common incubator at 37 ℃.
The culture target: selecting a single colony of the frozen and preserved thallus, placing the single colony in a liquid MRS liquid culture medium, and standing and culturing for about 24 hours in a common incubator at 37 ℃ to activate the mucous membrane lactobacillus CCFM1273.
(2) First-stage culture:
adopting MRS liquid culture medium, and static culturing in a common incubator at 37 ℃.
The culture target: the activated lactobacillus mucosae CCFM1273 with the inoculation amount of 1 percent of the culture medium volume is transferred to the MRS liquid culture medium for two generations.
(3) Secondary culture:
transferring the lactobacillus mucosae CCFM1273 subjected to primary culture to a 1LMRS liquid culture medium according to the inoculation amount of 1% of the volume of the culture medium, performing static culture in a common incubator at 37 ℃ for about 24 hours, and collecting thalli. Washed twice with PBS pH7.4, then resuspended in 30% glycerol solution with viable count of 2.2X 10 10 CFU/mL, when used in subsequent experiments, glycerol was discarded by centrifugation, washed once with physiological saline and resuspended in physiological saline.
Example 3: determination of gastrointestinal fluid tolerance of lactobacillus mucosus CCFM1273
Assay method to simulate survival in gastrointestinal fluids: the artificial simulated gastrointestinal fluid needs to be prepared fresh. Pepsin (national Shanghai test, 64008860) was dissolved in PBS (pH3.0) to a final concentration of 3g/L, and was filtered through a 0.22 μm filter membrane to prepare a simulated gastric fluid. Trypsin (shanghai bio-engineering ltd., a 003319-0001) was dissolved in PBS having a ph of 8.0 to a final concentration of 1g/L, and filtered through a 0.22 μm filter to prepare a simulated intestinal fluid. Centrifuging cultured mucous membrane lactobacillus at 4 deg.C at 6000rpm for 10min, collecting bacterial sludge, re-suspending with 0.85% physiological saline, and regulating bacterial liquid density to 1 × 10 in simulated gastric juice (pH 3.0) 9 CFU/mL. After mixing uniformly, placing the mixture at 37 ℃ for culturing for 2h, and counting the number of viable bacteria. Adding 1mL of the bacterial liquid treated by simulated gastric juice into 9mL of simulated intestinal juice (pH8.0), uniformly mixing, culturing at 37 ℃, and detecting the number of viable bacteria after 4 hours. The percentage of the ratio of the number of the treated living bacteria to the number of the initial living bacteria is the survival rate.
The results show that the survival rate of CCFM1273 in simulated gastric fluid is 87.43% and in simulated intestinal fluid is 78.81%.
Example 4: lactobacillus mucosus CCFM1273 can improve the weight, liver weight, epididymal fat and perirenal fat of nonalcoholic fatty liver mice
1. Laboratory animal
Male SPF grade C57BL/6J mice (4 weeks old, weight 20-23 g), from Zhejiang Uygon Rilly laboratory animal technology, inc., china. Mice were housed in polypropylene cages containing 8 mice per group, food and water, temperature (22 ℃), relative humidity (50 ± 10%), free drinking water, control mice fed on standard diet, model building and CCFM1273 mice fed on 60% fat high fat diet (TP 23300) from southernwood technologies ltd.
2. Experimental method
(1) Establishment of non-alcoholic fatty liver mouse model
The control mice are fed with standard feed, the mice of the molding group, CCFM1273 and FGSYC17L3 group are fed with 60 percent high-fat feed, the mice are freely drunk for 12 weeks, the weight is weighed every week, and after 12 weeks, the weight of the molding group is 25 percent higher than that of the control group, namely the molding is considered to be successful.
(2) Experimental grouping and administration
32C 57BL/6J mice were randomly divided into 4 groups, i.e., control group, modeling group, lactobacillus mucosus CCFM 1273-treated group and Lactobacillus mucosus FGSYC17L 3-treated group, each group consisting of 8 mice. The administration mode of the mucous membrane lactobacillus treatment group is intragastric administration, and the intragastric administration dosage is 4 multiplied by 10 10 CFU/100 μ L/day. And (3) performing intragastric administration on the mucous membrane lactobacillus treatment model every day, and performing intragastric administration on both the normal group and the model group as a control till the end of the experiment.
During the mouse molding, the body weight of the mouse was weighed weekly.
After 12 weeks of molding, the molded group had a weight 25.81% higher than that of the control group, the FGSYC17L3 group was equivalent to that of the molded group, and the CCFM1273 group was 19.89% higher than that of the control group and 4.70% lower than that of the molded group. After sacrifice, the liver, epididymal fat and perirenal fat were weighed separately.
As shown in FIG. 1, the weight of the liver of the model group is 16.41% higher than that of the control group, the weight of the epididymal fat is 387.40% higher than that of the control group, and the weight of the perirenal fat is 509.85% higher than that of the control group; the weight of liver of the CCFM1273 group is 6.37 percent lower than that of the model, the weight of epididymal fat is 15.53 percent lower than that of the model, and the weight of perirenal fat is 21.60 percent lower than that of the model. This indicates that the mucomyxolactobacillus CCFM1273 can reduce the weight of mouse liver and epididymis fat and significantly reduce the weight of perirenal fat (P < 0.05).
Example 5: lactobacillus mucosus CCFM1273 improves liver fat accumulation of nonalcoholic fatty liver mice
The molding and grouping processing are performed in the same manner as in example 4.
After the experiment, the mice were sacrificed, a part of liver tissues was dissected, blood was washed clean with physiological saline, fixed with 4% paraformaldehyde for 24 hours, dehydrated, paraffin-embedded, and frozen and sectioned. Then, ultrathin sections (4 μm) were washed with isopropyl alcohol and stained with oil red O staining solution. The stained sections were coverslipped with neutral gum as adhesive. A pathological section scanner is used to record the micrographs.
As shown in FIG. 2, the fat accumulation in the liver of the non-alcoholic fatty liver disease mouse is increased, the number of lipid droplets is increased in an oil red slice, the area of the lipid droplets is increased, and the severity of the non-alcoholic fatty liver disease can be reflected. When the fat ratio in the section is analyzed by using software Image Pro Plus, the fat ratio in the model group is remarkably increased (P < 0.05) compared with that in the blank group, and the fat area in the lactobacillus mucosus CCFM1273 group is reduced from 22.61% to 11.70% of that in the model group, so that the fat accumulation in the liver of a mouse with nonalcoholic fatty liver disease can be improved.
The results show that the fat accumulation of liver of the mice in the model-making group is increased compared with that of the control group, the trend can be well relieved by the lactobacillus mucosus CCFM1273, and the FGSYC17L3 has no effect.
Example 6: mucous membrane lactobacillus strain CCFM1273 for improving area of fat cells of non-alcoholic fatty liver mice
The molding and grouping processing are performed in the same manner as in example 4.
After the experiment, the mice were sacrificed, part of perirenal adipose tissue was dissected, blood was washed clean with physiological saline, fixed with 4% paraformaldehyde for 24 hours, dehydrated, paraffin-embedded, and sectioned. Then, ultrathin sections (4 μm) were taken and stained with Hematoxylin and Eosin (HE). The stained sections were coverslipped with neutral gum as adhesive. A pathological section scanner is used to record the micrographs.
As shown in FIG. 3, the adipocytes of the non-alcoholic fatty liver disease mouse are large and loosely arranged. The size of the fat cells in the section is analyzed by using software FIJI, compared with a blank group, the size of the fat cells in the model group is obviously increased, and the area of the fat cells is increased to 2928.23 mu m 2 (P<0.05 And the area of fat cells of the mucous membrane lactobacillus CCFM1273 group is 2409.5 mu m 2 Can remarkably relieve the tendency of fat cell enlargement (P)<0.05 FGSYC17L3 had no such effect).
Example 7: lactobacillus mucosus CCFM1273 for reducing serum leptin level of nonalcoholic fatty liver mice
The molding and grouping processing are performed in the same manner as in example 4. After 24h of the last gastric lavage, blood samples are collected from orbital venous plexus, the blood is kept still, centrifuged for 4000g and 10min, and serum is obtained by centrifugation and stored in a refrigerator at the temperature of minus 80 ℃ for subsequent tests. The leptin level in the mouse serum was detected using an enzyme linked immunosorbent assay (ELISA).
Leptin, an endogenous hormone, is produced by adipocytes and secreted into the circulation. Leptin can regulate glycolipid and energy metabolism, and control appetite. Patients with non-alcoholic fatty liver disease develop leptin resistance, and serum leptin level is higher than normal. As shown in FIG. 4, compared with the normal group, the serum leptin level of the nonalcoholic fatty liver disease model mouse is significantly increased to 10.61ng/mL (P < 0.05), while the serum leptin level of the mucor lactobacillus mucosus CCFM1273 group is 5.31ng/mL, which can significantly reduce the serum leptin level of the mouse (P < 0.05), while the down-regulation effect of FGSYC17L3 is far inferior to that of CCFM1273.
Example 8: lactobacillus mucosus CCFM1273 for improving expression level of leptin mRNA in adipose tissue of mouse with nonalcoholic fatty liver disease
The molding and grouping processing are performed in the same manner as in example 4. After 24h of the last gavage, a part of the adipose tissues was taken and stored in a refrigerator at-80 ℃ for subsequent experiments. In the experiment, adipose tissues are taken out, total RNA of the adipose tissues is extracted by using a Trizol method, and the relative expression quantity of leptin mRNA of the adipose tissues of the mice is detected by using a quantitative PCR (qPCR) method after the total RNA is reversely transcribed into cDNA.
As shown in fig. 5. Compared with the control group, the relative expression of leptin mRNA of the model group mice is remarkably increased to 3.85 (P < 0.05), and the expression level of leptin is remarkably increased to 3.10 in the lactobacillus mucosus CCFM1273 group, which shows that the expression level of leptin can be well reduced by the lactobacillus mucosus CCFM1273, but FGSYC17L3 has no effect.
Example 9: lactobacillus mucosus CCFM1273 for improving expression level of leptin receptor mRNA of liver tissue of non-alcoholic fatty liver mice
The molding and grouping processing are performed in the same manner as in example 4. After 24h of the last gavage, a part of liver tissue was taken and stored in a refrigerator at-80 ℃ for subsequent experiments. During the experiment, liver tissues are taken out, total RNA of adipose tissues is extracted by using a Trizol method, and the relative expression quantity of the leptin receptor mRNA of the mouse liver tissues is detected by using a quantitative PCR (qPCR) method after the total RNA is reversely transcribed into cDNA.
As shown in fig. 6, compared with the control group, the leptin receptor expression level of the model group mice is significantly reduced to 0.08 (P < 0.05), while that of the lactobacillus mucosus CCFM1273 group is 0.43, which indicates that the lactobacillus mucosus CCFM1273 can well increase the leptin receptor expression level, while the FGSYC17L3 has no effect.
The results of examples 4 to 9 show that the lactobacillus mucosus CCFM1273 can relieve leptin resistance of a mouse, improve liver fat accumulation and fat cell size, and has a good regulation effect on the weight of the mouse, the weight of the liver, the weight of epididymal fat and the weight of perirenal fat, and finally shows a significant relieving effect on non-alcoholic fatty liver. It can be used for preparing medicine or health product for preventing and treating non-alcoholic fatty liver, or producing food beneficial for reducing weight, such as food additive for probiotic beverage, sour soybean milk, fermented jelly, fermented tea beverage or dairy products (such as yogurt, cheese product, lactobacillus, milk powder), etc. Example 10: tablet containing lactobacillus mucosus CCFM1273 microbial inoculum
The specific manufacturing process comprises the following basic steps: activation of strains → enlarged culture → collection of strains → preparation of bacterial suspension → freeze drying → total mixing → tabletting.
1. Activating strains: the lactobacillus mucosus CCFM1273 is statically cultured in MRS liquid culture medium in a common incubator at 37 ℃ in an inoculation amount of 1 percent of the volume of the culture medium, and is continuously activated for two generations.
2. And (3) amplification culture: transferring the activated lactobacillus mucosus CCFM1273 to 1L of MRS liquid culture medium according to the inoculation amount of 1 percent of the volume of the culture medium for amplification culture, and performing static culture in a common incubator at 37 ℃ for 24h.
3. Collecting thalli and preparing bacterial suspension: after the completion of the scale-up culture, the cells were collected by centrifugation at a low temperature of 4 ℃ and washed twice with PBS (pH 7.4), and then made into 10 by using an aqueous solution of 13% by weight of skim milk 10 CFU/mL of bacterial suspension.
4. And (3) freeze drying: and preparing the bacterial suspension into bacterial powder according to a conventional freeze drying process.
5. Total mixing: adding stearic acid 2% of total weight of the fungus powder as lubricant, and CMC-Na 3% of total weight of the fungus powder as binder, and mixing.
6. Tabletting: tabletting by a tabletting machine according to conventional tabletting processes.
Example 11: powder preparation containing lactobacillus mucosus CCFM1273 microbial inoculum
The specific manufacturing process comprises the following basic steps: activation of bacterial species → enlargement → collection of bacterial cells → preparation of bacterial suspension → activation of freeze-dried bacterial species, enlargement, collection of bacterial cells, preparation of bacterial suspension as in example 2.
And (3) freeze drying: preparing the bacterial suspension into freeze-dried thallus powder according to the conventional freeze-drying process
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. A mucous membrane lactobacillus (Lactobacillus mucosae) CCFM1273 is deposited in Guangdong province collection center at 9-8 months in 2022, and the deposit number is GDMCC No:62775.
2. a microbial preparation comprising Lactobacillus mucosae CCFM1273 according to claim 1.
3. The microbial preparation of claim 2, wherein the viable count of the lactobacillus mucosae strain CCFM1273 is not less than 1 x 10 10 CFU/g or 1X 10 10 CFU/mL。
4. Use of lactobacillus mucosae CCFM1273 according to claim 1 for the preparation of a medicament for the prevention and/or treatment of non-alcoholic fatty liver disease.
5. Use of lactobacillus mucosae CCFM1273 according to claim 1 in the preparation of a health care product for controlling body fat and/or maintaining healthy levels of blood lipids.
6. A product containing lactobacillus mucosus CCFM1273 according to claim 1.
7. The product of claim 6, wherein the product is a food product, a nutraceutical product, or a pharmaceutical product.
8. The product according to claim 6 or 7, characterized in that the viable count of the lactobacillus mucosae CCFM1273 in the product is not less than 1 x 10 10 CFU/g。
9. The product according to claim 9, wherein the drug comprises the lactobacillus mucosus CCFM1273, a pharmaceutical carrier and/or a pharmaceutical excipient; the food comprises dairy products, bean products, meat products or fruit and vegetable products which are produced by using the lactobacillus mucosae CCFM1273.
10. Use of lactobacillus mucosus CCFM1273 according to claim 1 in food additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310424.9A CN115449496A (en) | 2022-10-25 | 2022-10-25 | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211310424.9A CN115449496A (en) | 2022-10-25 | 2022-10-25 | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115449496A true CN115449496A (en) | 2022-12-09 |
Family
ID=84311270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211310424.9A Pending CN115449496A (en) | 2022-10-25 | 2022-10-25 | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115449496A (en) |
-
2022
- 2022-10-25 CN CN202211310424.9A patent/CN115449496A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113234640B (en) | Bifidobacterium longum MF-269 and application thereof | |
| CN112322527A (en) | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof | |
| CN111996153B (en) | Bifidobacterium breve and application thereof | |
| CN113943681B (en) | Bifidobacterium longum capable of reducing inflammatory reaction and relieving constipation | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN114214230B (en) | Lactobacillus North with helicobacter pylori copolymerization capability and application thereof | |
| CN113337440B (en) | Lactobacillus salivarius MG-587 and application thereof | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN115478036A (en) | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver disease and application thereof | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN112239739A (en) | Lactobacillus plantarum capable of relieving ETEC (enterotoxigenic enterobacteria) induced diarrhea and application thereof | |
| CN115992076B (en) | Lactobacillus fermentum with blood sugar reducing function and application thereof | |
| CN116445356A (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| CN114410532B (en) | Bifidobacterium longum capable of reducing plasma trimethylamine oxide and cecum trimethylamine levels and application thereof | |
| CN112877260B (en) | Lactobacillus paracasei for relieving purgative colon and application thereof | |
| CN113913330B (en) | Lactobacillus plantarum for regulating OVA-specific IgE and application thereof | |
| JP2013133312A (en) | Therapeutic agent for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis | |
| CN116024129A (en) | Lactobacillus crispatus capable of co-aggregating with helicobacter pylori and application thereof | |
| CN116064313A (en) | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue | |
| CN115449496A (en) | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver leptin resistance and application thereof | |
| CN114381406A (en) | Bifidobacterium breve CCFM1217 capable of simultaneously reducing blood plasma and caecum trimethylamine and application thereof | |
| CN115449497A (en) | Mucous membrane lactobacillus capable of regulating liver lipid metabolism and application thereof | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN114874954B (en) | Lactobacillus curvatus capable of promoting production of short chain fatty acid in intestinal tract and application thereof | |
| CN114561325B (en) | Bifidobacterium longum capable of changing bile acid content in simulated gastrointestinal tract environment and having constipation relieving effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |